Cortagen
Status
No approved product. No FDA-approved labeling exists. Not an FDA-approved medicine. Status in Russia and other countries was not verified for this entry.
What it is
A short peptide studied in Russian work for nerve tissue.
What published research measured
A synthetic short peptide from the Khavinson programme directed at cerebral cortex tissue, developed as a defined analogue of the brain extract Cortexin, and reported in that group's work to support recovery in peripheral nerve injury and cognitive function. The distinction between the extract and the synthetic derivative applies here as it does across the category: the older clinical literature concerns the tissue extract, which is a registered medicine in Russia, while the product usually sold is the short synthetic peptide with a much thinner evidence base. This entry does not cite registered trials, independent replication or published human pharmacokinetic data.
Source
Khavinson programme publications; Cortexin extract literature
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.